2-(N-tert.-Butyl-N-methylamino)-ethanol | 19672-71-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(N-tert.-Butyl-N-methylamino)-ethanol
• 英文别名: N-Methyl-N-tert.-butyl-2-amino-ethanol；2-[Tert-butyl(methyl)amino]ethanol
• CAS: 19672-71-0
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: QXGNZOSBXJWNOR-UHFFFAOYSA-N

物化性质

• 沸点：
  174.1±13.0 °C(Predicted)
• 密度：
  0.881±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(N-tert.-Butyl-N-methylamino)-ethanol 在 三乙胺 、 甲烷磺酰基叠氮化物 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 16.0h， 生成 2-(N-tert-Butyl-N-methylamino)ethyl 2-diazoacetoacetate
  参考文献：
  名称：

  Applications of Stevens [1,2]-Shifts of Cyclic Ammonium Ylides. A Route to Morpholin-2-ones

  摘要：

  2-(N,N-Dialkylamino)ethyl diazoacetoacetates 2 were prepared in two steps from readily available ethanolamines 1. When heated in the presence of catalytic Cu, the substrates cleanly formed morpholinones 3, presumably via the intermediacy of copper carbenoids and cyclic ammonium ylides. In most cases involving benzylic or allylic migrating groups, ylide [1,2]-shift occurred in good yield (55-80%). In the case of benzhydryl containing substrate 2g, only dimer 4 was isolated. Simple alkyl groups failed to undergo the rearrangement, with the exception of tert-butyl case 2i, which furnished morpholinone 3i in low yield. Substituted allylic case 2l gave only [1,2]-shift product 3l, with no evidence for competing [2,3]-shift to give 3l'. Diazoacetates 2n-p also underwent conversion to morpholinones 3n-p in 19-64% yield with Cu(acac)(2) catalysis.

  DOI：

  10.1021/jo00099a041
• 作为产物：
  描述：

  tert-butyl-(2-hydroxyethyl)-(methoxymethyl)-methylazanium;bromide 在 2,3-二巯基丁二酸 作用下， 生成 2-(N-tert.-Butyl-N-methylamino)-ethanol 、 N-[2-(methoxymethoxy)ethyl]-N,2-dimethylpropan-2-amine
  参考文献：
  名称：

  Bystrova, L. P.; Kuznetsov, S. G.; Chigareva, S. M., Journal of Organic Chemistry USSR (English Translation), 1980, vol. 16, p. 1549 - 1553

  摘要：

  DOI：

文献信息

• EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145026A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b and R 5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了根据式I合成的化合物、药用可接受的配方和用途，或其立体异构体、互变异构体或药用可接受的盐。对于式I化合物X、Y、R1、R2、R3a、R3b、R4a、R4b和R5如规范中所定义。这些创新的式I化合物是eIF4A的抑制剂，在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160289212A1

  公开（公告）日：2016-10-06

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： X-A-Y-Z-L-R 1 （I） 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20170197986A1

  公开（公告）日：2017-07-13

  Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种二氢嘧啶并环衍生物作为HBV抑制剂，特别涉及一种如下式（I）所示的化合物或其药用可接受的盐。
• HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF
  申请人：Cheng Jianjun

  公开号：US20140206679A1

  公开（公告）日：2014-07-24

  The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

  本发明涉及一种由通式(I)表示的杂环吡啶酮化合物，其中该杂环吡啶酮化合物用作酪氨酸激酶抑制剂，特别是c-Met抑制剂。本发明还涉及用于制备杂环吡啶酮化合物的中间体和制备方法。本发明还涉及一种包含杂环吡啶酮化合物作为活性成分的药物组合物，以及药物组合物在治疗与酪氨酸激酶c-Met相关的疾病，特别是与c-Met相关的癌症作为药物的用途。
• 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
  申请人：Mayer Scott Christian

  公开号：US20090264427A1

  公开（公告）日：2009-10-22

  Imidazole-substituted 4-anilino-3-cyanoquinolines are described, which selectively inhibit IFGR kinase activity and are useful for treating disorders associated with IGFR kinases.

  描述了咪唑取代的4-苯胺基-3-氰基喹啉类化合物，其选择性抑制IGFR激酶活性，并可用于治疗与IGFR激酶相关的疾病。